Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Open-label Study in Japan to Investigate the Efficacy, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment naïve, Genotype 1, Chronic Hepatitis C Subjects
Brief Summary: The purpose of this study is to evaluate effectiveness, safety and pharmacokinetics (Explores what the body does to the medication) of TMC435350 in combination with Peginterferon Alfa-2a and Ribavirin in genotype 1 hepatitis C virus infected Japanese participants who have never received treatment for their hepatitis C infection.


Options:
A: Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin | Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Placebo for ribavirin | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV, ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Placebo for ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
B: Arm Label: 20mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 48mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 120mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 240mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 240mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 120mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 48mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 20mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Immediate Treatment Group; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir 100mg / Elbasvir 50 mg FDC | Arm Label: Deferred Treatment Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Grazoprevir 100mg / Elbasvir 50 mg FDC, Drug: Placebo to Grazoprevir / Elbasvir 50 mg FDC | Intervention Type: DRUG; Name: Grazoprevir 100mg / Elbasvir 50 mg FDC; Assigned to Arm(s): Deferred Treatment Group, Immediate Treatment Group | Intervention Type: DRUG; Name: Placebo to Grazoprevir / Elbasvir 50 mg FDC; Assigned to Arm(s): Deferred Treatment Group
D: Arm Label: TMC12/PR24 50 mg; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Arm Label: TMC12/PR24 100 mg; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Arm Label: TMC24/PR24 50 mg; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Arm Label: TMC24/PR24 100 mg; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Arm Label: PR48 Control; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): PR48 Control, TMC12/PR24 100 mg, TMC12/PR24 50 mg, TMC24/PR24 100 mg, TMC24/PR24 50 mg | Intervention Type: DRUG; Name: PegIFNα-2a; Assigned to Arm(s): PR48 Control, TMC12/PR24 100 mg, TMC12/PR24 50 mg, TMC24/PR24 100 mg, TMC24/PR24 50 mg | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): PR48 Control, TMC12/PR24 100 mg, TMC12/PR24 50 mg, TMC24/PR24 100 mg, TMC24/PR24 50 mg

Answer: D